

Preface

OVER 22 MILLION PEOPLE ARE ALIVE TODAY SUFFERING FROM CANCER and half of those cancers share a precise common molecular feature. That feature is a mutation in the *p53* gene (see chapter by Olivier et al.) that alters its function. That these mutations play a major role in the development of malignancy is supported by the tragedy of Li-Fraumeni syndrome. This devastating cancer family syndrome is caused by germ line mutations in *p53* that predispose affected individuals to the early onset of a wide range of malignancies. It is the ubiquity of *p53* alterations in so many different types of human cancer that has focused such intense interest in understanding the *p53* gene and its protein product for the last 30 years.

An enormous amount has been learnt about how *p53* functions to reduce the incidence of cancer (Zilfou and Lowe) and new therapies based upon our understanding of *p53* are now in the clinic. The intensity of investigation has produced an intellectual dilemma, which the chapters in this book attempt to resolve. Is the ubiquity of *p53* in non-neoplastic processes as apparently diverse as human reproduction (Hu), metabolism (Feng; Gottlieb and Vousden), development (Storer and Zon), drug and radiation toxicity (Gudkov and Komarova), and aging (Donehower) a unique feature of *p53* as a transcription factor (Beckerman and Prives) or does it rather reflect the immense interconnections within signaling pathways in cells and the sensitivity of the tools developed in the *p53* system to demonstrate these connections?

Starting with chapters (Belyi et al.; Rutkowski et al.) describing the origins and evolution of the *p53* family genes in invertebrates and vertebrates, which emphasize their high level of conservation, the book then explores the complexity with which that genetic information is expressed, producing many isoforms (Khoury and Bourdon) of the three family members *p53*, *p63*, and *p73* (Dötsch et al.) in vertebrates.

Lack of *p53* results in an increased incidence of cancer, while an overactive *p53* can induce accelerated aging in vertebrates. The correct regulation of the *p53* response to stress is vital for its effective function. The study of the control of *p53* has been enormously exciting and at the cutting edge of modern molecular technology, from detailed structural investigations of its folding, stability, and oligomerization (Joerger and Fersht), through to analysis of its many post translational modifications (Meek and Anderson) and its molecular partners (Lu). Two negative regulators of *p53* function, *Mdm2* and *Mdm4*, play an essential role in controlling *p53* and this has been elegantly explored in mouse models (Perry; Lozano). Remarkably, polymorphisms have been described in the *p53* system in man that reflect on all these activities and the chapter by Grochola et al. updates the provocative observations that subtle human variations in *p53* and *Mdm2*/*Mdm4* activity can affect human cancer incidence and outcome. The pace of discovery in the field is quickening rather than slackening and it has become a model system of choice for many investigations in biology (Lane and Levine). The utility of these advanced studies is beginning to be realized both in disease diagnosis and prognosis (Robles and Harris) and in drug development (Lane et al.; Gudkov and Komarova), where a number of exciting pre-clinical molecules are under evaluation and *p53* gene therapy approved in some countries. Indeed, the recent strong mouse model support for the earlier concepts that expressed mutant *p53* proteins have new “gains of function” that can drive invasion and metastasis and block differentiation coupled with increased understanding of the control of expression of mutant *p53* proteins may resolve long standing issues of interpretation of *p53*'s role in tumor pathology (Oren and Rotter).

We hope that by bringing together a unique gathering of experts this volume will provide a great introduction to the field for newcomers to the p53 family and a starting off point for vigorous debate among the converted. The many unknowns in this system that are detailed and discussed in this volume provide us all with inspiration for future work.

We are grateful to Richard Sever at the Cold Spring Harbor Laboratory Press for his vision and encouragement and to Kaaren Kockenmeister for her organization of the production of the book. We would also like to acknowledge Joan Ebert, without whom this book might not have happened, for her dedication and persistence in managing the manuscripts in the face of great prevarication. We are enormously indebted to the team of authors who took time out from their investigations to consider their work in a broader context and share it with us all.

DAVID LANE
*A*Star, Singapore*

ARNIE LEVINE
Institute for Advanced Study, Princeton

Index

A

- ABP (amyloid β -peptide), 330
ACC (adrenocortical carcinoma), 141, 142
Acetylation, 255–257
Actinomycin D, 307, 310
Acute ischemia, 324–325
Acute myeloid leukemia (AML), 46
Adenovirus gene therapy, 294–295
Adrenocortical carcinoma (ACC), 141, 142
ADULT syndrome, 58
Advexin, 293, 294
AEC (Hay-Wells syndrome), 58, 216
Aflatoxin B1, 145–146
African Americans, 214
Africans, 2–4
Aging and longevity
 conclusions and future studies, 232–233
 life-span reduction in p53 null mice, 222
 p53's role in humans, 325–327
 regulation in mice, 229–232
AKT. *See* IGF-1/AKT/mTOR pathways
Akt kinase, 112–114
Alzheimer's disease, 330
Amino-terminal transactivation domain (TAD), 26–28,
 49, 50–51, 84–86
AML (acute myeloid leukemia), 46
Amphioxus, 8
AMPK (AMP-activated protein kinase), 200–201, 203
Amyloid β -peptide (ABP), 330
Ankryin repeat domain 11 (ANKD11), 116
Ankyloblepharon, ectodermal dysplasia, and clefting
 syndrome (AEC), 216
Annelid worm (*Capitella*), 280
Antirepression of p53, 176–177
Apoptosis
 anticancer functions of p53 and, 225–227
 p53 as a determinant of acute radiosensitivity and,
 320
 p53's role in, 180–181
 in vivo evidence for p53 role in, 257–258
APR-246. *See* PRIMA-1^{MET}
ARF-Bp1, 31
ARF gene, 11, 104, 224–225
Arg337, 25
Arginine, 89
Artiodactyla, 4
Asians, 2–4, 214
Asp228, 32–33
Asp352, 25
ASPP family of proteins, 74
Ataxia telangiectasia mutated (ATM), 101, 165,
 223, 229
ATM and Rad 9-related protein (ATR), 103,
 114, 223
Autophagy, 179–180, 201
Autoregulation of p53
 conclusions and future studies, 118–119
 control of the p53/mdm2 lifeline
 by nontranscriptional targets of p53,
 114–115
 by transcriptional targets of p53, 112–114
 controls among siblings, 117–118
 direct regulation of p53's activity, 115–117
 loops overview, 111
 p53/mdm2 negative-feedback loop, 111–112
 regulation of p53 expression independent of mdm2,
 115
 tissues grouped according to signal response,
 109–110
B
Balkan endemic nephropathy (BEN), 132, 134
Brachistoma floridae (Florida lancelet), 281
BRCA1, 74, 230
Breast cancer
 isoforms of the p53 family and, 46
 TP53 abnormalities as biomarkers of cancer prog-
 nosis, 147–148
Breast Cancer Association Consortium (BCAC), 163
BubR1, 54
C
c-Abl, 58
Caenorhabditis elegans (round worms)
 DNA binding domains and p53, 6
 evolution of p53 and, 52
 evolution of the functions of p53 genes and, 9
 oligomerization domain, 25
 p53 homologs in, 7
 p53 superfamily in, 281–282, 285–288
 p63/p73 homolog, 8
 primordial functions of p53 family in, 210

Cancer

- anticancer functions of p53 in mice
 - apoptosis, 225–227
 - attenuation of, 228–229
 - DNA damage response, 222–224
 - oncogenic stress, 224–225
 - senescence, 225–227
 - contribution of TP53 to cancers (*see* TP53 mutations in human cancers)
 - isoforms of the p53 family and, 46–47
 - metabolism and (*see* Regulation of metabolic pathways by p53)
 - mutp53 GOF (*see* Mutant p53 gain-of-function in cancer)
 - p53-based therapy (*see* p53-based cancer therapy)
 - p53/p63/p73 family pathway and, 30–33
 - p53 pathway targeting for therapies, 30–32
 - phosphorylation of serines 6 and 9 and, 86–87
 - prevention using p53, 10
 - targeting of p53 cancer mutations, 32–33
 - tetramer formation and, 25
 - therapies derived from structural information, 30
 - therapy based on p53 (*see* p53-based cancer therapy)
 - tumorigenesis role of p53 family members, 53–54
 - tumor suppression (*see* Tumor suppressive functions of p53)
- Capitella* (annelid worm), 280
- Capsaspora owczarzaki*, 282
- Carboxy-terminal regulatory domain (CTD), 28
- Cardiotoxicity, 331
- Carnavora, 4
- CARPs, 31
- Caspase-8 D302H, 162–163
- Caucasians, 2–4, 214–215
- Caveolin-1, 205
- CDK, 227
- CDKN1A, 163–164
- CEP-1, 9, 23, 25, 52, 285–288
- CHK1, 103
- Chmp4C, 205
- Choanoflagellates, 8
- Choanozoans, 280, 282
- Ciona intestinalis* (urochordate), 281
- Ciona savignyi* (urochordate), 281
- Cisplatin-induced nephrotoxicity, 331
- Clams, 8, 282–283
- Clinical outcomes from TP53 studies
 - assessment of p53 status
 - functional analysis, 145
 - gene sequencing, 144
 - immunohistochemistry, 144
 - mass spectrometry, 145
 - microarray analysis, 145
 - TP53 mutational load assay, 145
 - conclusions and future studies, 150–152

- genetic variants used as biomarkers of cancer risk and outcome, 142
- germline mutations and inherited cancer predisposition, 141–142, 143f
- microRNAs studies and, 150, 151f
- somatic mutations and, 142, 143f, 146–147
- TP53 abnormalities as biomarkers
 - of breast cancer, 147–148
 - of colorectal cancer, 147
 - of exposure to environmental carcinogens, 145–146
 - of head and neck cancers, 148
 - of hematopoietic cancers, 149
 - of lung cancer, 148–149
 - of lymphoid cancers, 149
 - of ovarian cancer, 149
 - of prostate cancer, 149
 - of therapeutic response, 149–150
- cMyc, 69, 242
- Cockayne syndrome B protein (CSB), 194
- Codon72, 158–159
- Colon carcinomas, 47
- Colorectal cancer, 147
- COP1, 31, 115
- CP-31398, 301
- Crassostrea gigas* (oyster), 282–283
- CSB (Cockayne syndrome B protein), 194
- CTD (carboxy-terminal regulatory domain), 28
- Cyclin-dependent kinase cyclin A/cdk2, 114, 227
- Cyclotherapy, 310–311
- Cys220, 32–33

D

- Δ 133p53 isoform, 42, 43, 45, 270–271
- D302H, 162–163
- Damage-regulated autophagy modulator (DRAM), 179, 203, 205
- Danio rerio*. *See* Zebrafish
- DBC1 protein, 31
- Delta9-THC, 330
- Diamond-Blackfan syndrome, 104
- Dmp53, 210
- DNA binding domains and p53, 6, 21–23, 64–66
- DNA-PK, 223
- Δ Np63 and zebrafish development, 274–275
- DRAM (damage-regulated autophagy modulator), 179, 203, 205
- DRB, 307
- Drosophila* (fruit flies)
 - DNA binding domains and p53, 6
 - evolution of p53 and, 52
 - evolution of the functions of p53 genes and, 9
 - oligomerization domain, 25
 - p53 homologs in, 7
 - p53 superfamily in, 281–282

p53 superfamily protein function in, 283–285
p63/p73 homolog, 8
primordial functions of p53 family in, 210

E

Ectodermal dysplasia syndromes (ED), 58
Ectrodactyly-ectoderma, dysplasia-clefting
(EEC syndrome), 58, 216
Elephant shark, 8
Embryonal rhabdomyosarcoma (ERMS), 270
Endosomal compartment, 204–205
ESCRT-III, 205
Euprymna scolopes (Hawaiian bobtail squid), 282–283
EX-527, 304

F

Fish nevi (f-nevi), 269
Flavopiridol, 307
Florida lancelet (*Brachistoma floridae*), 281
4EBP1 protein, 201
Fruit flies. *See Drosophila*

G

Gain-of-function studies (GOF). *See* Mutant p53
gain-of-function in cancer
G-allele of MDM2 SNP309, 161, 214, 215–216
Gendicine, 293, 294–295
GI tract and p53, 323f
Glu349, 25
GLUT1 and GLUT4, 192
Glutamine, 189
Glycolysis and cancer cells, 188–189
GOF (gain-of-function studies). *See* Mutant p53
gain-of-function in cancer
GSH/GSSG, 190

H

HATs (histone acetyltransferases), 66
HauSp (Herpes virus-associated ubiquitin-specific
protease), 214
Hawaiian bobtail squid (*Euprymna scolopes*), 282–283
Hay-Wells syndrome (AEC), 58
HCC (hepatocellular carcinomas), 145
HD (Huntington's disease), 330
HDACs (histone deacetylases), 302
Head and neck cancers, 148, 294–295
Helobdella robusta (leech), 280
Hematopoietic cancers, 149
Hepatocellular carcinomas (HCC), 145
Herpes virus-associated ubiquitin-specific protease
(HauSp), 214
HIF (hypoxia inducible factor), 189, 193–194

Histone acetyltransferases (HATs), 66
Histone deacetylases (HDACs), 302
HUF Assay (Hupki fibroblast assay), 133–134
Huntington's disease (HD), 330
HupKi mouse model, 124, 133–134
Hypoxia inducible factor (HIF), 189, 193–194

I

IARC TP53 database, 124, 131, 147
IGF-1/AKT/mTOR pathways
conclusions and future studies, 205–206
IGF-1/AKT pathway, 202
mTOR, 11, 199–202
p53 regulation of, 202–204
p53 regulation of endosomal compartment,
204–205
IGF-BP3 protein, 203
Inflammation and p53, 325–326
Invertebrate p53 superfamily proteins
in *Caenorhabditis*, 285–288
conclusions and future studies, 288–289
in *Drosophila*, 283–285
function in early animals, 282
isoforms and function in molluscs, 282–283
phylogenetic relationship, 280–282
Ionizing radiation, 100–103
Ischemia, acute, 324–325
Isoforms of the p53 family
antibodies for, 43, 44f
biological and molecular activities, 43, 45
cancer and, 46–47
conservation of dual gene structure, 40–42
p53's function as a protein, 39–40
of p63 and p73, 40
regulation of expression, 45

K

K120 acetylation, 88
K370, 89
KMT3C, 89

L

L5 ribosomal protein, 114
L11 ribosomal protein, 114
L23 ribosomal protein, 114
Lampreys, 8
Lancelet, 8
Leech (*Helobdella robusta*), 280
Leptomycin B (LMB), 305–306
Leu344, 24
Leukemia inhibitory factor (LIF), 211, 215, 260
Li-Fraumeni syndrome (LFS), 123, 126, 127f, 141–142
Limb mammary syndrome, 58, 216

Liver toxicity, 331

LMB (Leptomycin B), 305–306

Lophotrochozoa, 280

Lung cancer, 148–149

Lymphoid cancers, 149

Lysine, 89

M

Malignant peripheral neural sheath tumors (MPNSTs),
268–269, 271–272

MDM2 and MDM4

activation of p53 due to cell culture stress, 104–105

amino-terminal phosphorylation and, 84–86

cancer therapies and, 30–32

conclusions and future studies, 105

control of the p53/mdm2 lifeline

by nontranscriptional targets of p53, 114–115

by transcriptional targets of p53, 112–114

G-allele SNP309, 159–162, 214, 215–216

influence on p53 cell cycle arrest, senescence, and
apoptosis, 99–100

influence on response to ionizing radiation,
100–103

influence on response to ultraviolet radiation,
103–104

inhibition in response to oncogenic activation, 104

inhibition of the p53/Mdm2 interaction for cancer
therapy, 298–300

mouse models with constitutively active p53 and,
260–262

p53/mdm2 negative-feedback loop, 111–112

p53 pathway role in human reproduction, 214

regulation of p53, 12–14

regulation of p53 expression independent of mdm2,
115

relationship between, 98–99

ribosomal stress and activation of p53, 104

role of, 97–98

stability of mutp53 and, 249

MDMX

cancer therapies and, 30–32

inhibitors, 300–301

MEFs (murine embryonic fibroblasts), 177, 182

Melanoma

cooperativity of p53 in BRAF mutations in zebrafish,
269–270

isoforms of the p53 family and, 46

Metformin, 195

Methylene quinuclidinone, 302

microRNAs, 150, 151f, 272–273

miR-34a, 116–117

mitfa-*BRAF*^{V600E}, 269–270

Molluscs, 280, 282–283

Monosiga brevicollis, 282

Mosquitos, 7

Mouse models of p53 functions

aging and longevity, 229–232

anticancer functions of p53 in mice

apoptosis, 225–227

attenuation of, 228–229

DNA damage response, 222–224

oncogenic stress, 224–225

senescence, 225–227

conclusions and future studies, 263–264

with constitutively active p53, 260–262

differentiation/development role, 259–260

disruption of the p53 pathway, 263

life-span reduction in p53 null mice, 222

mutant p53 functions, 262

p53 cell cycle arrest/senescence and tumor
suppression, 258–259

stem cells role, 260

in vivo evidence for p53 role in apoptosis, 257–258

in vivo redundancy in upstream signals, 255–257

MPNSTs (malignant peripheral neural sheath tumors),
268–269, 271–272

Mre1 1-Rad50-NBS1 (MRN) complex, 248

mTOR. *See* IGF-1/AKT/mTOR pathways

mtp53-codon72-Arg, 159

Murine embryonic fibroblasts (MEFs), 177, 182

Mussels, 282–283

Mutant p53 gain-of-function in cancer

animal models, 243–244

biochemical basis of

gene expression patterns effects, 245

protein-protein interactions, 248

structural subgroups of mutations, 244–245

transcriptional effects, 246–248

biological manifestations in cultured cells

antiapoptosis, 242

biological effects of mutp53, 243

cell migration and invasion, 242–243

genomic instability, 241

TGF- β pathway, 243

conclusions and future studies, 249–250

definition of GOF, 240

history of GOF research, 240–241

stabilization of mutant p53 in cancer cells, 248–249

types of outcomes from mutations, 239–240

Mya arenaria (clam), 8, 282–283

Mytilus edulis (mussel), 282–283

Mytilus trossulus (mussel), 282–283

N

NADPH, 189, 190

Nematostella vectensis (sea anemone), 6, 8, 9, 280,
281–282

Neuronal development and differentiation, 56–57

NF- κ B, 326, 330, 348, 349

Non-small cell lung carcinoma (NSCLC), 294

Nuclear export, 305–306
Nutlins, 30, 69, 293, 300, 301, 307, 309
Nyp-63, 6

O

Onyx 015, 295–296
Opisthokonts, 280
Otototoxicity, 331
Ovarian cancer, 149
Oyster (*Crassostrea gigas*), 282–283

P

p21
activation of, 66
cell cycle arrest and tumor suppression, 258–259
codon31, 163–164
MDM4 and, 98, 100
p53 effector functions and, 177, 178, 181, 183
p53 isoforms activities and, 40, 43, 45
p53/mdm2 lifeline and, 112
posttranslational modifications of p53 and, 87, 88
senescence and, 227
transcription initiation and, 67, 68, 70, 72, 73, 74
p27-79C/T, 164
p300/CBP, 26, 66–67, 84–86
transcription modifications by, 71, 72
P47S, 127
p53-based cancer therapy
activation of p53 using drug combinations, 309–310
adenovirus-based therapy with Onyx 015, 295–296
antisense and siRNA approaches, 296
conclusions and future studies, 311
current approaches, 293–294
cyclotherapy, 310–311
gene therapy-based approaches, 294–295
inhibition of the p53/Mdm2 interaction, 298–300
MdmX inhibitors, 300–301
small molecule activation of p53
family members in a p53 mutant or deficient
background, 307–309
by inhibition of nuclear export, 305–306
by inhibition of sirtuins, 302–304
by transcriptional inhibition and nucleolar disruption, 306–307
via direct interaction with p53, 301–302
small molecule approaches to, 297–298
synthetic lethality, 298
tumor specific vaccines use, 296–297
p53 β isoform, 43, 45
p53/p63/p73 family
cancer therapy from structural information, 30
conclusions and future studies, 12–14, 33
development regulation role, 11–12
diversity signaling, 26–28
DNA-binding domain structure, 20–21
domain structure of the proteins, 4–5
drug development, 346
evolutionary history, 1–2, 9–11
extreme carboxyl terminus behavior, 28
functions unique to p63 and p73 (*see* p63 and p73)
future studies
cancer research, 350–351
combinatorial complexity issues, 346–347
intrinsic and extrinsic stress signals, 348–350
model systems research's potential, 347–348
homologs or paralogs of, 6–9
limitations of evolutionary studies, 5–6
pathway targeting for cancer therapy, 30–32
regulation of metabolic pathways (*see* Regulation of metabolic pathways by p53)
regulation of p53-mediated stress response (*see* MDM2 and MDM4)
reproduction role (*see* Reproduction and p53)
research history, 343–346
SNPs in the signaling pathway (*see* Single-nucleotide polymorphisms and p53 signaling)
structural basis of sequence-specific DNA binding, 21–23
structural basis of tetramer formation, 23–25
structural evolution of tetramerization, 25–26
structure of the full-length protein, 28–30
structure of the genes in humans, 2–4
targeting of p53 cancer mutations, 32–33
tumor suppressive functions (*see* Tumor suppressive functions of p53)
p53R172R, 258, 262
p63 and p73. *See also* p53/p63/p73 family
conclusions and future studies, 59
evolution of, 51–53
functions, 50
G4C14-to-A4T14, 164–165
genetic abnormalities from p63 dysfunction, 58–59
isoforms of, 40
mutant p53 gain-of-function in cancer and, 246–248
neuronal development and differentiation role, 56–57
oocyte function role, 57–58
regulation by autoregulation loops, 117–118
skin and epithelial development role, 55, 56f
structural features, 49–51
tumorigenesis role, 53–54
P72R polymorphism, 128–129, 142
PALA, 307
Parkinson's disease, 330
Pathologies associated with the p53 response
acute ischemia and, 324–325
antitumor effects of p53, 327–328
conclusions and future studies, 335

Pathologies associated with the p53 response

(continued)

- mechanisms underlying tissue-specific effects of p53, 322, 324
 - p53 as a determinant of acute radiosensitivity, 318–320
 - p53 as a radiosensitizer in the GI tract, 321–322, 323f
 - p53 inhibition as a therapeutic strategy, 318
 - p53's role in regulation of inflammation and aging, 325–327
 - potential applications of p53 inhibitors
 - p53 effects independent of PFT α , 332
 - PFT α , 328–329
 - PFT α and autophagy, 332
 - PFT α and neuropathology, 328–329
 - PFT α prevention of certain toxicities, 331
 - rescue of mice from developmentally lethal gene defects, 331–332
 - risks associated with PFT α , 333
 - safety issues associated with use of p53 inhibitors, 332–334
 - translation of experimental p53 suppression into clinical use, 334–335
- Pax-3 gene, 331–332
- PC4, 115–116
- Pentose phosphate pathway (PPP), 189, 190, 192
- Peptides and MDM2 inhibition, 298–300
- PFT α . *See* Pifithrin- α
- PFT μ , 334
- Phikan083, 32–33, 320
- Phosphatidylinositol kinase-related family (PIKK), 200, 222–223
- Phosphorylation of p53. *See also* Posttranslational modification of p53
 - control of the p53/mdm2 lifeline and, 112–114
 - in vivo redundancy in upstream signals and, 255–257
- PI3 kinase (PI3K), 202
- Pifithrin- α (PFT α)
 - about, 328–329
 - autophagy and, 332
 - and neuropathology, 329–331
 - p53 effects independent of, 332
 - prevention of certain toxicities, 331
 - rescue of mice from developmentally lethal gene defects, 331–332
 - risks associated with, 333
- PIKK (phosphatidylinositol kinase-related family), 200, 222–223
- Pirh2, 31–32, 115
- Placozoa (*Trichoplax adherens*), 280
- PML (promyelocytic leukemia), 248
- Posttranslational modification of p53
 - acetylation's role in regulating p53 function, 87–89
 - amino-terminal phosphorylation and, 84–86

- conclusions and future studies, 90–92
 - induction and activation of p53, 83–84
 - introduction and historical perspective, 81–82
 - methylation of lysine and arginine, 89
 - phosphorylation of serines 6 and 9, 86–87
 - reversibility of, 89–90
 - sequential and interdependent character of, 82–83
- PPM1D(WIP1), 90
- PPP (pentose phosphate pathway), 189, 190, 192
- PRIMA-1^{MET}, 30, 297–298, 301–302
- Promyelocytic leukemia (PML), 248
- Prostate cancer, 149
- PTEN, 203
- PUMA, 117, 180–181, 184
- Pyrazofurin, 307

R

- Radiosensitivity, 318–320
- Rapp-Hodgkin syndrome (RHS), 58, 216, 217
- RAS mutations, 270
- RCC (renal cell carcinoma), 46–47
- Reactivation of transcriptional reporter activity (RETRA), 308–309
- Reactive oxygen species (ROS), 189–190, 192–193, 201
- REDD1 and REDD2, 201
- Regulation of IGF-1/AKT/mTOR pathways. *See* IGF-1/AKT/mTOR pathways
- Regulation of metabolic pathways by p53
 - conclusions and future studies, 195
 - metabolism and cancer
 - anabolic pathways regulation, 189
 - energy production regulation, 188–189
 - ROS and cell fate, 189–190
 - role of p53
 - as an antioxidant, 192–193
 - functions of p53, 190–191
 - glycolysis regulation, 192
 - hypoxia and, 193–194
 - oxidative phosphorylation regulation, 191–192
 - tumor suppression and promotion by p53-induced pathways, 194–195
- Renal cell carcinoma (RCC), 46–47
- Renal toxicity, 331
- Reproduction and p53
 - conclusions and future studies, 217
 - fertility and, 211
 - infertility in women and, 215–216
 - p53 pathway role in humans, 213–217
 - p63, 211–213
 - p73, 213
 - primordial functions of p53 family in invertebrates, 210
 - protein domains, 210–211
- RETRA (reactivation of transcriptional reporter activity), 308–309

Rhabdomyosarcoma (RMS), 270
RHS (Rapp-Hodgkin syndrome), 58, 216, 217
Ribosomal stress and activation of p53, 104
RING-finger domains of MDM2, 99
RITA, 302
RMS (rhabdomyosarcoma), 270
RNA polymerase II (RNAPII), 66, 70
ROS (reactive oxygen species), 189–190,
192–193, 201
Roscovitine, 307
Round worms. *See Caenorhabditis elegans*

S

S46 phosphorylation, 71, 127
S6K, 201
S7 ribosomal protein, 114
SAM (sterile alpha motive), 59, 210–211
Sea anemone (*Nematostella vectensis*), 6, 8, 9, 210, 280,
281–282
Sea urchins, 7
Seladin-1 (DHCR24) protein, 225
Senescence
 anticancer functions of p53 and, 227–228
 mouse models of tumor suppression and, 258–259
 p53's role in, 177–179
Ser15, 82–83
Ser49Cys, 165
Serines 6 and 9, 86–87
SHSF (split hand split foot malformation), 58, 216–217
Single-nucleotide polymorphisms and p53 signaling
 conclusions and future studies, 167, 168–169t
 functional p53 pathway SNPs
 MDM2 SNP309, 159–162
 p53 codon72, 158–159
 p53 pathway role in human reproduction, 213–216
 potential functional p53 pathway SNPs
 ATM Ser49Cys, 165
 caspase-8 D302H, 162–163
 p21 codon31, 163–164
 p27-79C/T, 164
 p73 G4C14-to-A4T14, 164–165
 screens for identifying potential functional pathway
 SNPs, 165–167
siRNA approaches to cancer therapy, 296
Sirtinol, 303–304
Sirtuins (SIRT1), 31, 90, 116–117, 302–304
Skin and epithelial development, 55, 56f
Slug, 117
SNP309, 159–162
SNPs in the signaling pathway. *See* Single-nucleotide
 polymorphisms and p53 signaling
Sp1 transcription factor, 160–161
Spinal cord death, 330–331
Spisula solidissima (clam), 282–283
Split hand split foot malformation (SHSF), 58, 216–217

Splitomycin, 304
Sterile alpha motive (SAM), 59, 210–211
Strongylocentrotus purpuratus, 280
Super p53 mice, 231–232
Suramin, 304
Synapsida, 4
Synthetic lethality, 298

T

TAD (transactivation domain), 26–28, 49, 50–51,
84–86, 245–248
TAp73, 53, 57–58, 275–276
Tenovins, 31, 304
3,2',3',4'-Tetrahydroxycalcone, 304
Tetramer formation, 23–25
TIGAR, 192
Tobacco and G-to-T transversions, 146
TOPORS, 31
TP53 mutations in human cancers
 biomarkers' use in clinics, 134–135
 biomarkers' use in molecular
 epidemiology, 134
 clinical outcomes and correlates (*see* Clinical
 outcomes from TP53 studies)
 conclusions and future studies, 135–136
 contribution of TP53 to cancers, 123
 germline mutations, 126, 127f
 mutagen-induced spectra
 experimental systems, 133–134
 human data, 131–133
 polymorphisms, 127–129
 somatic mutations, 124–126
 structural and functional impact
 dominant-negative and gain-of-function effects,
 130–131
 on protein structure, 129
 on transcriptional activities, 129–130
Transactivation domain (TAD), 26–28, 49, 50–51,
84–86, 245–248
Transcriptional regulation by p53
 conclusions and future studies, 75
 features commonly associated with transcriptional
 regulators, 63–64
 mechanics of
 acetylation, 66
 DNA binding, 64–66
 p53-mediated repression, 70
 transcription elongation, 69–70
 transcription initiation, 66–69
 promoter selectivity
 binding partners, 73–75
 modifications, 71–73
 p53 response elements, 71
 role as a sequence-specific DNA binding protein, 64
Trichoplax adherens (placozoa), 280

TRIM24, 31

TSAP6, 204–205

TSC1-TSC2, 203

Tumor suppressive functions of p53

conclusions and future studies, 184

context dependence, 182–183

mechanisms of context

dependence, 183–184

models for p53 activation, 175–177

p53 effector functions

apoptosis, 180–181

autophagy, 179–180

cell-cycle checkpoints, 177

cellular senescence, 177–179

functions crucial to tumor suppression, 181–182

Tyr220, 32–33

U

Ultraviolet radiation, 103–104

Urochordates, 281

V

V217M, 127

Vibrio fischeri, 282–283

W

Warburg effect, 188, 193–194, 349

X

Xenopus, 6, 87, 211

Y

Y220C, 32–33

Z

Zebrafish

conservation of p53 structure and function in,
267–268

cooperativity of p53 in BRAF mutations, 269–270

cooperativity of p53 in RAS mutations, 270

$\Delta 113$ p53 and, 42, 45

regulation of p53 in

$\Delta 113$ p53 regulation of p53-mediated apoptosis,
270–271

by miRNAs, 272–273

ribosomal proteins, 271–272

ribosomal stress and activation of p53, 104

role of p53 family members in development,
273–274

ΔN p63 and ectodermal development, 274–275

TAp73 requirement for normal embryonic
development, 275–276

role of p53 in morpholino

toxicity, 273

tumor formation in p53 mutants, 268–269

Zmpste24, 230